Acacia Research Corporation (NASDAQ: ACTG) announced today that a subsidiary has acquired 13 US and foreign patents and applications on fluorescence microscopy. “Acacia continues to increase the number of leading patent portfolios in the medical device and life sciences space,” commented Matt Vella, CEO. “Fluorescence microscopy is of key relevance to the life sciences because it enables three-dimensional imaging of cellular constituents with unrivaled specificity.” ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation’s subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Information about Acacia Research Corporation and its subsidiaries is available at and www.acaciaresearch.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements including those of Matthew Vella relating to our licensing success, the number of technology companies selecting us as their partner, and the growth of our base of future revenues are based upon our current expectations and speak only as of the date hereof. Our ability to become the licensing partner for companies, and our ability to grow our base of future revenues by adding new patent portfolios may differ materially and adversely from that expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, the ability to successfully develop licensing programs and attract new business, rapid technological change in relevant markets, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general, and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.